Auven Therapeutics
10
62M
3
0.71
2
0.70
3
- Areas of investment
Summary
Auven Therapeutics is the famous VC, which was founded in 2007. The main department of described VC is located in the Delray Beach. The company was established in North America in United States.
The increased amount of exits for fund were in 2016. Deals in the range of 50 - 100 millions dollars are the general things for fund. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Auven Therapeutics performs on 4 percentage points less the average number of lead investments. The top activity for fund was in 2009. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 investment rounds annually.
The fund was created by Peter Corr. The overall number of key employees were 2.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Auven Therapeutics, startups are often financed by AstraZeneca, Tichenor Ventures, Purdue Pharma. The meaningful sponsors for the fund in investment in the same round are AstraZeneca, Tichenor Ventures, Redmile Group. In the next rounds fund is usually obtained by AstraZeneca, HBM Healthcare Investments AG, Tichenor Ventures.
Among the most popular fund investment industries, there are Health Care, Medical. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Spirogen, Kolltan Pharmaceuticals.
Investments analytics
Analytics
- Total investments
- 10
- Lead investments
- 2
- Exits
- 3
- Rounds per year
- 0.71
- Follow on index
- 0.70
- Investments by industry
- Medical (10)
- Biotechnology (10)
- Therapeutics (6)
- Biopharma (6)
- Pharmaceutical (3) Show 1 more
- Investments by region
-
- Switzerland (6)
- United States (3)
- United Kingdom (1)
- Peak activity year
- 2009
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 15
- Avg. valuation at time of investment
- 225M
- Group Appearance index
- 0.80
- Avg. company exit year
- 11
- Avg. multiplicator
- 4.19
- Strategy success index
- 0.67
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ADC Therapeutics | 26 Mar 2012 | Biotechnology, Medical, Therapeutics, Biopharma | Early Stage Venture | 50M | Switzerland, Vaud, Lausanne |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.